Colossal Biosciences, valued at approximately $10.2–$11 billion after its latest large funding round led by TWG Global, is a biotechnology company advancing genetic engineering and de-extinction technologies. Headquartered in Dallas, Texas, United States, the company is developing tools to revive extinct species and support biodiversity through advanced CRISPR, genomics, and synthetic biology. Founded in 2021, Colossal has drawn global attention for its ambitious projects including efforts around the woolly mammoth, thylacine, and dodo bird.
Keep reading to learn how Colossal Biosciences raised capital and gained high-profile backers in its rapid growth journey.
What Is Colossal Biosciences and What Does It Do?
Founded in 2021 by entrepreneur Ben Lamm and Harvard geneticist George Church, Colossal Biosciences is a biotech company building tools in genetic engineering to pursue “de-extinction” and conservation genomics. The company applies advanced CRISPR genome-editing methods, data-driven biology, and computational platforms to explore species restoration, enhance endangered species survival, and create research spin-offs in related biotech fields.
Colossal operates labs and research partnerships in the United States and internationally, working with academic institutions and conservation groups to advance both fundamental science and applied genetic technologies.
How Much Funding Has Colossal Biosciences Raised?
1. Series A Round
- Amount Raised: $60 million
- Date: March 2022
- Lead Investors: Thomas Tull, At One Ventures, early biotech and strategic investors
- Purpose: Establish genetic engineering research, build core technology, and hire scientific teams
2. Series B Round
- Amount Raised: $162.6 million
- Date: July 2024
- Lead Investors: United States Innovative Technology Fund (USIT), Animal Capital, Bold Capital, Breyer Capital, In-Q-Tel, Jazz Ventures, Peak6, Robert Nelsen, Us Innovative Technology Fund, Victor Vescovo, Westriver Group
- Purpose: Advance de-extinction projects, scale lab operations, and fund species-specific research initiatives
3. Series C Round
- Amount Raised: $320 million
- Date: September 2025
- Lead Investors: TWG Global (co-led by Mark Walter and Thomas Tull), Peter Jackson, Robert Nelsen, US Innovative Technology Fund
- Purpose: Accelerate genetic engineering capabilities, expand species portfolio, and support hardware/software innovation for genomics research
- Valuation: Around $10.2 billion–$11 billion post-money
Total Funding Raised: Approximately $568 million+ across all rounds
Latest Funding Date: September 2025
Latest Known Valuation: Around $10.2–11 billion after Series C expansion
Key Investors
- Mark Walter / TWG Global
- Details: Co-founder of TWG Global, investment figure with ventures in technology, media, financial services, and sports.
- Focus Areas: Strategic growth capital, biotech innovation, and de-extinction technologies.
- Role: Led Series C financing for Colossal Biosciences alongside Thomas Tull.
- Thomas Tull
- Details: Billionaire investor and film producer, co-chair of TWG Global and early Colossal investor.
- Focus Areas: Technology, biotech, AI, and advanced scientific ventures.
- Role: Major backer from Series A and through later rounds.
- United States Innovative Technology Fund (USIT)
- Details: Venture capital firm focused on cutting-edge technology companies.
- Focus Areas: Genomics, synthetic biology, and emerging tech innovation.
- Role: Led Series B funding and participated across rounds.
- Animal Capital
- Details: Investment firm that supports disruptive and mission-driven technology companies.
- Focus Areas: Environmental tech, biotech, species conservation.
- Role: Participated in Series B round.
- Animoca Brands & Bold Capital
- Details: Strategic and venture investors with interests in emerging tech.
- Focus Areas: Digital innovation, biotech ventures, and transformative platforms.
- Role: Backed Colossal’s Series B financing.
- Breyer Capital & Peak6
- Details: Prominent venture investors with historical support of tech growth companies.
- Focus Areas: Cross-sector technology expansion.
- Role: Contributed to Series B and expansion financing.
Where Is Colossal Biosciences’s Headquarters?
Colossal Biosciences is headquartered in Dallas, Texas, United States, with additional research operations and lab partnerships across Boston, Melbourne, and other scientific hubs supporting its multidisciplinary programs.
What’s Next for Colossal Biosciences?
Colossal intends to deploy its latest capital to expand its genetic engineering infrastructure, deepen scientific research into de-extinction and conservation applications, and build out hardware and computational platforms to support its biotechnology stack. The company is also exploring commercial spin-outs that leverage core technologies for human healthcare, plastic degradation solutions, and computational biology services.
Get Investor and Funding Insights with TexAu
TexAu provides verified investor and funding data for companies like Colossal Biosciences. Explore insights on biotech platforms, synthetic biology, and high-growth innovation companies shaping the future of genetics and conservation technology.
Sign up for Free to access real time investor and funding intelligence.